Fig. 1: Overview of comparative PALOMA-2/3 biomarker analysis described in this study.
From: Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
ET endocrine therapy; GE gene expression; PAL palbociclib; PCA principal component analysis; PFS progression-free survival; MBC metastatic breast cancer; Tx treatment.
